Literature DB >> 24807786

Myostatin regulates energy homeostasis in the heart and prevents heart failure.

Nadine Biesemann1, Luca Mendler1, Astrid Wietelmann1, Sven Hermann1, Michael Schäfers1, Marcus Krüger1, Thomas Boettger1, Thilo Borchardt2, Thomas Braun2.   

Abstract

RATIONALE: Myostatin is a major negative regulator of skeletal muscle mass and initiates multiple metabolic changes, including enhanced insulin sensitivity. However, the function of myostatin in the heart is barely understood, although it is upregulated in the myocardium under several pathological conditions.
OBJECTIVE: Here, we aimed to decipher the role of myostatin and myostatin-dependent signaling pathways for cardiac function and cardiac metabolism in adult mice. To avoid potential counterregulatory mechanisms occurring in constitutive and germ-line-based myostatin mutants, we generated a mouse model that allows myostatin inactivation in adult cardiomyocytes. METHODS AND
RESULTS: Cardiac MRI revealed that genetic inactivation of myostatin signaling in the adult murine heart caused cardiac hypertrophy and heart failure, partially recapitulating effects of the age-dependent decline of the myostatin paralog growth and differentiation factor 11. We found that myostatin represses AMP-activated kinase activation in the heart via transforming growth factor-β-activated kinase 1, thereby preventing a metabolic switch toward glycolysis and glycogen accumulation. Furthermore, myostatin stimulated expression of regulator of G-protein signaling 2, a GTPase-activating protein that restricts Gaq and Gas signaling and thereby protects against cardiac failure. Inhibition of AMP-activated kinase in vivo rescued cardiac hypertrophy and prevented enhanced glycolytic flow and glycogen accumulation after inactivation of myostatin in cardiomyocytes.
CONCLUSIONS: Our results uncover an important role of myostatin in the heart for maintaining cardiac energy homeostasis and preventing cardiac hypertrophy.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  AMP-activated protein kinases; biochemistry; cardiomegaly; heart failure; metabolism; myostatin

Mesh:

Substances:

Year:  2014        PMID: 24807786     DOI: 10.1161/CIRCRESAHA.115.304185

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  35 in total

1.  GDF11 Decreases Pressure Overload-Induced Hypertrophy, but Can Cause Severe Cachexia and Premature Death.

Authors:  Shavonn C Harper; Jaslyn Johnson; Giulia Borghetti; Huaqing Zhao; Tao Wang; Markus Wallner; Hajime Kubo; Eric A Feldsott; Yijun Yang; Yunichel Joo; Xinji Gou; Abdel Karim Sabri; Priyanka Gupta; Maria Myzithras; Ashraf Khalil; Michael Franti; Steven R Houser
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

Review 2.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

3.  Plasma growth differentiation factors 8 and 11 levels in cats with congestive heart failure secondary to hypertrophic cardiomyopathy.

Authors:  V K Yang; J E Rush; S Bhasin; A J Wagers; R T Lee
Journal:  J Vet Cardiol       Date:  2019-09-01       Impact factor: 1.701

4.  Analysis of Cre-mediated genetic deletion of Gdf11 in cardiomyocytes of young mice.

Authors:  Jessica Garbern; Amy C Kristl; Vinicius Bassaneze; Ana Vujic; Henk Schoemaker; Rebecca Sereda; Liming Peng; Elisabeth M Ricci-Blair; Jill M Goldstein; Ryan G Walker; Shalender Bhasin; Amy J Wagers; Richard T Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 5.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

6.  Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy.

Authors:  Estibaliz Castillero; Hirokazu Akashi; Catherine Wang; Marc Najjar; Ruiping Ji; Peter J Kennel; H Lee Sweeney; Paul C Schulze; Isaac George
Journal:  Biochem Biophys Res Commun       Date:  2014-12-18       Impact factor: 3.575

7.  Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation.

Authors:  Javier Barallobre-Barreiro; Shashi K Gupta; Anna Zoccarato; Rika Kitazume-Taneike; Marika Fava; Xiaoke Yin; Tessa Werner; Marc N Hirt; Anna Zampetaki; Alessandro Viviano; Mei Chong; Marshall Bern; Antonios Kourliouros; Nieves Domenech; Peter Willeit; Ajay M Shah; Marjan Jahangiri; Liliana Schaefer; Jens W Fischer; Renato V Iozzo; Rosa Viner; Thomas Thum; Joerg Heineke; Antoine Kichler; Kinya Otsu; Manuel Mayr
Journal:  Circulation       Date:  2016-08-24       Impact factor: 29.690

Review 8.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

Review 9.  Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.

Authors:  Ryan G Walker; Tommaso Poggioli; Lida Katsimpardi; Sean M Buchanan; Juhyun Oh; Sam Wattrus; Bettina Heidecker; Yick W Fong; Lee L Rubin; Peter Ganz; Thomas B Thompson; Amy J Wagers; Richard T Lee
Journal:  Circ Res       Date:  2016-04-01       Impact factor: 17.367

10.  Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.

Authors:  Estibaliz Castillero; Hirokazu Akashi; Marc Najjar; Ruiping Ji; Lea Maria Brandstetter; Catherine Wang; Xianghai Liao; Xiaokan Zhang; Alexandra Sperry; Marcia Gailes; Karina Guaman; Adam Recht; Ira Schlosberg; H Lee Sweeney; Ziad A Ali; Shunichi Homma; Paolo C Colombo; Giovanni Ferrari; P Christian Schulze; Isaac George
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-12-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.